News

Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ a platform for recombinant viral vector manufacturing.
Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ a platform for recombinant viral vector manufacturing.

Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective viral safety testing approach of the product. 

read more
PathoQuest joins MabDesign
PathoQuest joins MabDesign

PathoQuest is a member of MabDesign, a membership organization dedicated to the creation of a unique environment that allows the economic development and growth of the French industrial sector in the field of therapeutic antibody and immunotherapy.

read more
PathoQuest achieves Illumina® Propel Certification

PathoQuest announced that it has received Propel Certification from Illumina after successfully completing the requirements for achieving this recognition. This included demonstrating the ability to produce high-quality data on the NexSeq System following a streamlined and rigorous process.

read more

Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.

Connect

 

EnglishFrenchGermanSpanish